AGE and RAGE inhibitors in the treatment of diabetic retinopathy

References

• Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care27(5), 1047–1053 (2004).
   PubMed Web of Science ®Google Scholar
• Fong DS, Sharza M, Chen W et al. Vision loss among diabetics in a group model Health Maintenance Organization (HMO). Am. J. Ophthalmol.133(2), 236–241 (2002).
   PubMed Web of Science ®Google Scholar
• Marshall SM, Flyvbjerg A. Prevention and early detection of vascular complications of diabetes. Br. Med. J333(7566), 475–480 (2006).
   PubMedGoogle Scholar
• American Diabetes Association: clinical practice recommendations 2002. Diabetes Care25(Suppl. 1), S1–S147 (2002).
   Web of Science ®Google Scholar
• Fong DS, Aiello L, Gardner TW et al. Retinopathy in diabetes. Diabetes Care27(Suppl. 1), S84–S87 (2004).
   PubMed Web of Science ®Google Scholar
• Klein BE, Davis MD, Segal P et al. Diabetic retinopathy. Assessment of severity and progression. Ophthalmology91(1), 10–17 (1984).
   PubMed Web of Science ®Google Scholar
• Stratton IM, Kohner EM, Aldington SJ et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia44(2), 156–163 (2001).
   PubMed Web of Science ®Google Scholar
• Retinopathy and nephropathy in patients with Type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N. Engl. J. Med.342(6), 381–389 (2000).
   PubMed Web of Science ®Google Scholar
• Chowdhury TA, Hopkins D, Dodson PM, Vafidis GC. The role of serum lipids in exudative diabetic maculopathy: is there a place for lipid lowering therapy? Eye16(6), 689–693 (2002).
   PubMed Web of Science ®Google Scholar
• Petrovic V, Bhisitkul RB. Lasers and diabetic retinopathy: the art of gentle destruction. Diabetes Technol. Ther.1(2), 177–187 (1999).
   PubMedGoogle Scholar
• Klein R, Klein BE, Moss SE. Epidemiology of proliferative diabetic retinopathy. Diabetes Care15(12), 1875–1891 (1992).
   PubMed Web of Science ®Google Scholar
• Frank RN. Diabetic retinopathy. N. Engl. J. Med.350(1), 48–58 (2004).
   PubMed Web of Science ®Google Scholar
• Engerman RL. Pathogenesis of diabetic retinopathy. Diabetes38(10), 1203–1206 (1989).
   PubMed Web of Science ®Google Scholar
• Tzekov R, Arden GB. The electroretinogram in diabetic retinopathy. Surv. Ophthalmol.44(1), 53–60 (1999).
   PubMed Web of Science ®Google Scholar
• Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Nakamura M. New insights into the pathophysiology of diabetic retinopathy: potential cell-specific therapeutic targets. Diabetes Technol. Ther.2(4), 601–608 (2000).
   PubMedGoogle Scholar
• Schmetterer L, Wolzt M. Ocular blood flow and associated functional deviations in diabetic retinopathy. Diabetologia42(4), 387–405 (1999).
   PubMed Web of Science ®Google Scholar
• Antonetti DA, Lieth E, Barber AJ, Gardner TW. Molecular mechanisms of vascular permeability in diabetic retinopathy. Semin. Ophthalmol.14(4), 240–248 (1999).
   PubMedGoogle Scholar
• Stitt AW, Anderson HR, Gardiner TA, Archer DB. Diabetic retinopathy: quantitative variation in capillary basement membrane thickening in arterial or venous environments. Br. J. Ophthalmol.78(2), 133–137 (1994).
   PubMed Web of Science ®Google Scholar
• vom Hagen F, Feng Y, Hillenbrand A et al. Early loss of arteriolar smooth muscle cells: more than just a pericyte loss in diabetic retinopathy. Exp. Clin. Endocrinol. Diabetes113(10), 573–576 (2005).
   PubMedGoogle Scholar
• Stitt AW, Gardiner TA, Archer DB. Histological and ultrastructural investigation of retinal microaneurysm development in diabetic patients. Br. J. Ophthalmol.79(4), 362–367 (1995).
   PubMed Web of Science ®Google Scholar
• Tilton RG, Chang K, Pugliese G et al. Prevention of hemodynamlemma and vascular albumin filtration changes in diabetic rats by aldose reductase inhibitors. Diabetes38(10), 1258–1270 (1989).
   PubMed Web of Science ®Google Scholar
• A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Sorbinil Retinopathy Trial Research Group. Arch. Ophthalmol.108(9), 1234–1244 (1990).
   PubMed Web of Science ®Google Scholar
• Sun W, Oates PJ, Coutcher JB, Gerhardinger C, Lorenzi M. A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy. Diabetes55(10), 2757–2762 (2006).
   PubMed Web of Science ®Google Scholar
• Curtis TM, Scholfield CN. The role of lipids and protein kinase Cs in the pathogenesis of diabetic retinopathy. Diabetes Metab. Res. Rev.20(1), 28–43 (2004).
   PubMed Web of Science ®Google Scholar
• Obrosova IG, Minchenko AG, Marinescu V et al. Antioxidants attenuate early upregulation of retinal vascular endothelial growth factor in streptozotocin-diabetic rats. Diabetologia44(9), 1102–1110 (2001).
   PubMed Web of Science ®Google Scholar
• Tooke J. Possible pathophysiological mechanisms for diabetic angiopathy in Type 2 diabetes. J. Diabetes Complications14(4), 197–200 (2000).
   PubMed Web of Science ®Google Scholar
• Miyata T, van Ypersele de Strihou C. Angiotensin II receptor blockers and angiotensin converting enzyme inhibitors: implication of radical scavenging and transition metal chelation in inhibition of advanced glycation end product formation. Arch. Biochem. Biophys.419(1), 50–54 (2003).
   PubMed Web of Science ®Google Scholar
• Aiello LP, Davis MD, Girach A for the PKC-DRS2 Group. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology113(12), 2221–2230 (2006).
   PubMed Web of Science ®Google Scholar
• Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature414(6865), 813–820 (2001).
   PubMed Web of Science ®Google Scholar
• Hammes HP, Du X, Edelstein D et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat. Med.9(3), 294–299 (2003).
   PubMed Web of Science ®Google Scholar
• Bucala R, Vlassara H. Advanced glycosylation end products in diabetic renal and vascular disease. Am. J. Kidney Dis.26(6), 875–888 (1995).
   PubMed Web of Science ®Google Scholar
• Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J. Intern. Med.251(2), 87–101 (2002).
   PubMed Web of Science ®Google Scholar
• Wautier JL, Guillausseau PJ. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab.27(5 Pt 1), 535–542 (2001).
   PubMed Web of Science ®Google Scholar
• Stitt AW, Jenkins AJ, Cooper ME. Advanced glycation end products and diabetic complications. Expert Opin. Investig. Drugs11(9), 1205–1223 (2002).
   PubMed Web of Science ®Google Scholar
• Monnier VM, Kohn RR, Cerami A. Accelerated age-related browning of human collagen in diabetes mellitus. Proc. Natl Acad. Sci. USA81(2), 583–587 (1984).
   PubMed Web of Science ®Google Scholar
• Hammes HP, Alt A, Niwa T et al. Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. Diabetologia42(6), 728–736 (1999).
   PubMed Web of Science ®Google Scholar
• Thornalley PJ. Dicarbonyl intermediates in the maillard reaction. Ann. NY Acad. Sci.1043, 111–117 (2005).
   PubMed Web of Science ®Google Scholar
• Baynes JW. The role of AGEs in aging: causation or correlation. Exp. Gerontol.36(9), 1527–1537 (2001).
   PubMed Web of Science ®Google Scholar
• Kuhla B, Luth HJ, Haferburg D et al. Methylglyoxal, glyoxal, and their detoxification in Alzheimer's disease. Ann. NY Acad. Sci.1043, 211–216 (2005).
   PubMed Web of Science ®Google Scholar
• Shinohara M, Thornalley PJ, Giardino I et al. Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. J. Clin. Invest.101(5), 1142–1147 (1998).
   PubMed Web of Science ®Google Scholar
• Baynes JW, Thorpe SR. Glycoxidation and lipoxidation in atherogenesis. Free Radic. Biol. Med.28(12), 1708–1716 (2000).
   PubMed Web of Science ®Google Scholar
• Genuth S, Sun W, Cleary P et al. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications participants with Type 1 diabetes. Diabetes54(11), 3103–3111 (2005).
   PubMed Web of Science ®Google Scholar
• Fosmark DS, Torjesen PA, Kilhovd BK et al. Increased serum levels of the specific advanced glycation end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with Type 2 diabetes mellitus. Metabolism55(2), 232–236 (2006).
   PubMedGoogle Scholar
• Nakamura N, Hasegawa G, Obayashi H et al. Increased concentration of pentosidine, an advanced glycation end product, and interleukin-6 in the vitreous of patients with proliferative diabetic retinopathy. Diabetes Res. Clin. Pract.61(2), 93–101 (2003).
   PubMed Web of Science ®Google Scholar
• Sugiyama S, Miyata T, Ueda Y et al. Plasma levels of pentosidine in diabetic patients: an advanced glycation end product. J. Am. Soc. Nephrol.9(9), 1681–1688 (1998).
   PubMed Web of Science ®Google Scholar
• Stitt AW, Li YM, Gardiner TA et al. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. Am. J. Pathol.150(2), 523–531 (1997).
   PubMed Web of Science ®Google Scholar
• Stitt AW, Bhaduri T, McMullen CB, Gardiner TA, Archer DB. Advanced glycation end products induce blood–retinal barrier dysfunction in normoglycemic rats. Mol. Cell Biol. Res. Commun.3(6), 380–388 (2000).
   PubMedGoogle Scholar
• Xu X, Li Z, Luo D et al. Exogenous advanced glycosylation end products induce diabetes-like vascular dysfunction in normal rats: a factor in diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol.241(1), 56–62 (2003).
   PubMedGoogle Scholar
• Kobayashi T, Oku H, Komori A et al. Advanced glycation end products induce death of retinal neurons via activation of nitric oxide synthase. Exp. Eye Res.81(6), 647–654 (2005).
   PubMed Web of Science ®Google Scholar
• Lecleire-Collet A, Tessier LH, Massin P et al. Advanced glycation end products can induce glial reaction and neuronal degeneration in retinal explants. Br. J. Ophthalmol.89(12), 1631–1633 (2005).
   PubMedGoogle Scholar
• Yao D, Taguchi T, Matsumura T et al. Methylglyoxal modification of mSin3A links glycolysis to angiopoietin-2 transcription. Cell124(2), 275–286 (2006).
   PubMedGoogle Scholar
• Stitt AW, Anderson HR, Gardiner TA, Bailie JR, Archer DB. Receptor-mediated endocytosis and intracellular trafficking of insulin and low-density lipoprotein by retinal vascular endothelial cells. Invest. Ophthalmol. Vis. Sci.35(9), 3384–3392 (1994).
   PubMed Web of Science ®Google Scholar
• Stitt AW, Burke GA, Chen F, McMullen CB, Vlassara H. Advanced glycation end-product receptor interactions on microvascular cells occur within caveolin-rich membrane domains. Faseb. J.14(15), 2390–2392 (2000).
   PubMed Web of Science ®Google Scholar
• Chen BH, Jiang DY, Tang LS. Advanced glycation end-products induce apoptosis involving the signaling pathways of oxidative stress in bovine retinal pericytes. Life Sci.79(11), 1040–1048 (2006).
   PubMed Web of Science ®Google Scholar
• Denis U, Lecomte M, Paget C et al. Advanced glycation end-products induce apoptosis of bovine retinal pericytes in culture: involvement of diacylglycerol/ceramide production and oxidative stress induction. Free Radic. Biol. Med.33(2), 236–247 (2002).
   PubMed Web of Science ®Google Scholar
• Yamagishi S, Fujimori H, Yonekura H, Tanaka N, Yamamoto H. Advanced glycation endproducts accelerate calcification in microvascular pericytes. Biochem. Biophys. Res. Commun.258(2), 353–357 (1999).
   PubMed Web of Science ®Google Scholar
• Liu B, Bhat M, Padival AK, Smith DG, Nagaraj RH. Effect of dicarbonyl modification of fibronectin on retinal capillary pericytes. Invest. Ophthalmol. Vis. Sci.45(6), 1983–1995 (2004).
   PubMed Web of Science ®Google Scholar
• Hughes SJ, Wall N, Scholfield CN et al. Advanced glycation endproduct modified basement membrane attenuates endothelin-1 induced [Ca2+]i signalling and contraction in retinal microvascular pericytes. Mol. Vis.10, 996–1004 (2004).
   PubMedGoogle Scholar
• Miller AG, Smith DG, Bhat M, Nagaraj RH. Glyoxalase I is critical for human retinal capillary pericyte survival under hyperglycemic conditions. J. Biol. Chem.281(17), 11864–11871 (2006).
   PubMed Web of Science ®Google Scholar
• Mamputu JC, Renier G. Signalling pathways involved in retinal endothelial cell proliferation induced by advanced glycation end products: inhibitory effect of gliclazide. Diabetes Obes. Metab.6(2), 95–103 (2004).
   PubMedGoogle Scholar
• Chibber R, Molinatti PA, Rosatto N, Lambourne B, Kohner EM. Toxic action of advanced glycation end products on cultured retinal capillary pericytes and endothelial cells: relevance to diabetic retinopathy. Diabetologia40(2), 156–164 (1997).
   PubMed Web of Science ®Google Scholar
• Stitt AW, McGoldrick C, Rice-McCaldin A et al. Impaired retinal angiogenesis in diabetes: role of advanced glycation end products and galectin-3. Diabetes54(3), 785–794 (2005).
   PubMed Web of Science ®Google Scholar
• Padayatti PS, Jiang C, Glomb MA, Uchida K, Nagaraj RH. High concentrations of glucose induce synthesis of argpyrimidine in retinal endothelial cells. Curr. Eye Res.23(2), 106–115 (2001).
   PubMed Web of Science ®Google Scholar
• Moore TC, Moore JE, Kaji Y et al. The role of advanced glycation end products in retinal microvascular leukostasis. Invest. Ophthalmol. Vis. Sci.44(10), 4457–4464 (2003).
   PubMed Web of Science ®Google Scholar
• Lu M, Kuroki M, Amano S et al. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J. Clin. Invest.101(6), 1219–1224 (1998).
   PubMed Web of Science ®Google Scholar
• Treins C, Giorgetti-Peraldi S, Murdaca J, Van Obberghen E. Regulation of vascular endothelial growth factor expression by advanced glycation end products. J. Biol. Chem.276(47), 43836–43841 (2001).
   PubMed Web of Science ®Google Scholar
• Gardiner TA, Anderson HR, Stitt AW. Inhibition of advanced glycation end-products protects against retinal capillary basement membrane expansion during long-term diabetes. J. Pathol.201(2), 328–333 (2003).
   PubMed Web of Science ®Google Scholar
• Kern TS, Engerman RL. Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin. Diabetes50(7), 1636–1642 (2001).
   PubMed Web of Science ®Google Scholar
• Du Y, Sarthy VP, Kern TS. Interaction between NO and COX pathways in retinal cells exposed to elevated glucose and retina of diabetic rats. Am. J. Physiol. Regul. Integr. Comp. Physiol.287(4), R735–R741 (2004).
   PubMed Web of Science ®Google Scholar
• Bolton WK, Cattran DC, Williams ME et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am. J. Nephrol.24(1), 32–40 (2004).
   PubMed Web of Science ®Google Scholar
• Taguchi T, Sugiura M, Hamada Y, Miwa I. In vivo formation of a Schiff base of aminoguanidine with pyridoxal phosphate. Biochem. Pharmacol.55(10), 1667–1671 (1998).
   PubMed Web of Science ®Google Scholar
• Yu PH, Zuo DM. Aminoguanidine inhibits semicarbazide-sensitive amine oxidase activity: implications for advanced glycation and diabetic complications. Diabetologia40(11), 1243–1250 (1997).
   PubMed Web of Science ®Google Scholar
• Misko TP, Moore WM, Kasten TP et al. Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur. J. Pharmacol.233(1), 119–125 (1993).
   PubMed Web of Science ®Google Scholar
• Forbes JM, Soulis T, Thallas V et al. Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia44(1), 108–114 (2001).
   PubMed Web of Science ®Google Scholar
• Voziyan PA, Metz TO, Baynes JW, Hudson BG. A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation. J. Biol. Chem.277(5), 3397–3403 (2002).
   PubMed Web of Science ®Google Scholar
• Nagaraj RH, Sarkar P, Mally A et al. Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: characterization of a major product from the reaction of pyridoxamine and methylglyoxal. Arch. Biochem. Biophys.402(1), 110–119 (2002).
   PubMed Web of Science ®Google Scholar
• Kang Z, Li H, Li G, Yin D. Reaction of pyridoxamine with malondialdehyde: mechanism of inhibition of formation of advanced lipoxidation end-products. Amino Acids30(1), 55–61 (2006).
   PubMed Web of Science ®Google Scholar
• Stitt A, Gardiner TA, Alderson NL et al. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes51(9), 2826–2832 (2002).
   PubMed Web of Science ®Google Scholar
• Alderson NL, Chachich ME, Youssef NN et al. The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int.63(6), 2123–2133 (2003).
   PubMed Web of Science ®Google Scholar
• Padival S, Nagaraj RH. Pyridoxamine inhibits maillard reactions in diabetic rat lenses. Ophthalmic Res.38(5), 294–302 (2006).
   PubMedGoogle Scholar
• Khalifah RG, Chen Y, Wassenberg JJ. Post-Amadori AGE inhibition as a therapeutic target for diabetic complications: a rational approach to second-generation Amadorin design. Ann. NY Acad. Sci.1043, 793–806 (2005).
   PubMed Web of Science ®Google Scholar
• Bakris GL, Bank AJ, Kass DA et al. Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process. Am. J. Hypertens.17(12 Pt 2), 23S–30S (2004).
   PubMed Web of Science ®Google Scholar
• Kass DA, Shapiro EP, Kawaguchi M et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation104(13), 1464–1470 (2001).
   PubMed Web of Science ®Google Scholar
• Liu J, Masurekar MR, Vatner DE et al. Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart. Am. J. Physiol. Heart Circ. Physiol.285(6), H2587–H2591 (2003).
   Web of Science ®Google Scholar
• Forbes JM, Yee LT, Thallas V et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes53(7), 1813–1823 (2004).
   PubMed Web of Science ®Google Scholar
• Figarola JL, Scott S, Loera S et al. LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats. Diabetologia46(8), 1140–1152 (2003).
   PubMed Web of Science ®Google Scholar
• Miyata T, Ueda Y, Asahi K et al. Mechanism of the inhibitory effect of OPB-9195 [(+/-)-2-isopropylide nehydrazono-4-oxo-thiazolidin-5-yl acetanilide] on advanced glycation end product and advanced lipoxidation end product formation. J. Am. Soc. Nephrol.11(9), 1719–1725 (2000).
   PubMed Web of Science ®Google Scholar
• Tsuchida K, Makita Z, Yamagishi S et al. Suppression of transforming growth factor β and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia42(5), 579–588 (1999).
   PubMed Web of Science ®Google Scholar
• Nakamura S, Makita Z, Ishikawa S et al. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes46(5), 895–899 (1997).
   PubMed Web of Science ®Google Scholar
• Seidler NW, Yeargans GS, Morgan TG. Carnosine disaggregates glycated α-crystallin: an in vitro study. Arch. Biochem. Biophys.427(1), 110–115 (2004).
   PubMed Web of Science ®Google Scholar
• Babizhayev MA, Deyev AI, Yermakova VN et al. Efficacy of N-acetylcarnosine in the treatment of cataracts. Drugs R D,3(2), 87–103 (2002).
   PubMedGoogle Scholar
• Stitt AW, He C, Friedman S et al. Elevated AGE-modified ApoB in sera of euglycemic, normolipidemic patients with atherosclerosis: relationship to tissue AGEs. Mol. Med.3(9), 617–627 (1997).
   PubMedGoogle Scholar
• Lu C, He JC, Cai W et al. Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells. Proc. Natl Acad. Sci. USA101(32), 11767–11772 (2004).
   PubMed Web of Science ®Google Scholar
• Stitt AW, He C, Vlassara H. Characterization of the advanced glycation end-product receptor complex in human vascular endothelial cells. Biochem. Biophys. Res. Commun.256(3), 549–556 (1999).
   PubMed Web of Science ®Google Scholar
• Zhu W, Sano H, Nagai R et al. The role of galectin-3 in endocytosis of advanced glycation end products and modified low density lipoproteins. Biochem. Biophys. Res. Commun.280(4), 1183–1188 (2001).
   PubMed Web of Science ®Google Scholar
• Iacobini C, Amadio L, Oddi G et al. Role of galectin-3 in diabetic nephropathy. J. Am. Soc. Nephrol.14(8 Suppl. 3), S264–S270 (2003).
   PubMed Web of Science ®Google Scholar
• Pugliese G, Pricci F, Iacobini C et al. Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice. Faseb. J.15(13), 2471–2479 (2001).
   PubMed Web of Science ®Google Scholar
• Iacobini C, Menini S, Oddi G et al. Galectin-3/AGE-receptor 3 knockout mice show accelerated AGE-induced glomerular injury: evidence for a protective role of galectin-3 as an AGE receptor. Faseb. J.18(14), 1773–1775 (2004).
   PubMedGoogle Scholar
• Tamura Y, Adachi H, Osuga J et al. FEEL-1 and FEEL-2 are endocytic receptors for advanced glycation end products. J. Biol. Chem.278(15), 12613–12617 (2003).
   PubMedGoogle Scholar
• Horiuchi S, Sakamoto Y, Sakai M. Scavenger receptors for oxidized and glycated proteins. Amino Acids25(3–4), 283–292 (2003).
   PubMed Web of Science ®Google Scholar
• Ohgami N, Nagai R, Ikemoto M et al. CD36, a member of class B scavenger receptor family, is a receptor for advanced glycation end products. Ann. NY Acad. Sci.947, 350–355 (2001).
   PubMedGoogle Scholar
• Unno Y, Sakai M, Sakamoto Y et al. Advanced glycation end products-modified proteins and oxidized LDL mediate down-regulation of leptin in mouse adipocytes via CD36. Biochem. Biophys. Res. Commun.325(1), 151–156 (2004).
   PubMed Web of Science ®Google Scholar
• Kuniyasu A, Ohgami N, Hayashi S et al. CD36-mediated endocytic uptake of advanced glycation end products (AGE) in mouse 3T3-L1 and human subcutaneous adipocytes. FEBS Lett.537(1–3), 85–90 (2003).
   PubMedGoogle Scholar
• Neeper M, Schmidt AM, Brett J et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem.267(21), 14998–15004 (1992).
   PubMed Web of Science ®Google Scholar
• Brett J, Schmidt AM, Yan SD et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am. J. Pathol.143(6), 1699–1712 (1993).
   PubMed Web of Science ®Google Scholar
• Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation114(6), 597–605 (2006).
   PubMed Web of Science ®Google Scholar
• Hudson BI, Stickland MH, Futers TS, Grant PJ. Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes50(6), 1505–1511 (2001).
   PubMed Web of Science ®Google Scholar
• Yonekura H, Yamamoto Y, Sakurai S et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem. J.370(Pt 3), 1097–1109 (2003).
   PubMed Web of Science ®Google Scholar
• Casselmann C, Reimann A, Friedrich I et al. Age-dependent expression of advanced glycation end product receptor genes in the human heart. Gerontology50(3), 127–134 (2004).
   Google Scholar
• Kaji Y, Amano S, Usui T et al. Expression and function of receptors for advanced glycation end products in bovine corneal endothelial cells. Invest. Ophthalmol. Vis. Sci.44(2), 521–528 (2003).
   PubMedGoogle Scholar
• Soulis T, Thallas V, Youssef S et al. Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia40(6), 619–628 (1997).
   PubMed Web of Science ®Google Scholar
• Hammes HP, Hoerauf H, Alt A et al. N(ε)(carboxymethyl)lysin and the AGE receptor RAGE colocalize in age-related macular degeneration. Invest. Ophthalmol. Vis. Sci.40(8), 1855–1859 (1999).
   PubMed Web of Science ®Google Scholar
• Howes KA, Liu Y, Dunaief JL et al. Receptor for advanced glycation end products and age-related macular degeneration. Invest. Ophthalmol. Vis. Sci.45(10), 3713–3720 (2004).
   PubMedGoogle Scholar
• Barile GR, Pachydaki SI, Tari SR et al. The RAGE axis in early diabetic retinopathy. Invest. Ophthalmol. Vis. Sci.46(8), 2916–2924 (2005).
   PubMed Web of Science ®Google Scholar
• Kislinger T, Fu C, Huber B et al. N(ε)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J. Biol. Chem.274(44), 31740–31749 (1999).
   PubMed Web of Science ®Google Scholar
• Valencia JV, Weldon SC, Quinn D et al. Advanced glycation end product ligands for the receptor for advanced glycation end products: biochemical characterization and formation kinetics. Anal Biochem,324(1), 68–78 (2004).
   Google Scholar
• Schmidt AM, Hori O, Chen JX et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J. Clin. Invest.96(3), 1395–1403 (1995).
   PubMed Web of Science ®Google Scholar
• Wautier JL, Schmidt AM. Protein glycation: a firm link to endothelial cell dysfunction. Circ. Res.95(3), 233–238 (2004).
   PubMed Web of Science ®Google Scholar
• Lander HM, Tauras JM, Ogiste JS et al. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J. Biol. Chem.272(28), 17810–17814 (1997).
   PubMed Web of Science ®Google Scholar
• Yamagishi S, Fujimori H, Yonekura H, Yamamoto Y, Yamamoto H. Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells. Diabetologia41(12), 1435–1441 (1998).
   PubMed Web of Science ®Google Scholar
• Shanmugam N, Kim YS, Lanting L, Natarajan R. Regulation of cyclooxygenase-2 expression in monocytes by ligation of the receptor for advanced glycation end products. J. Biol. Chem.278(37), 34834–34844 (2003).
   PubMed Web of Science ®Google Scholar
• Valencia JV, Mone M, Koehne C, Rediske J, Hughes TE. Binding of receptor for advanced glycation end products (RAGE) ligands is not sufficient to induce inflammatory signals: lack of activity of endotoxin-free albumin-derived advanced glycation end products. Diabetologia47(5), 844–852 (2004).
   PubMed Web of Science ®Google Scholar
• Collison KS, Parhar RS, Saleh SS et al. RAGE-mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs). J. Leukoc. Biol.71(3), 433–444 (2002).
   PubMed Web of Science ®Google Scholar
• Falcone C, Emanuele E, D'Angelo A et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler. Thromb. Vasc. Biol.25(5), 1032–1037 (2005).
   PubMed Web of Science ®Google Scholar
• Katakami N, Matsuhisa M, Kaneto H et al. Decreased endogenous secretory advanced glycation end product receptor in Type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care28(11), 2716–2721 (2005).
   PubMed Web of Science ®Google Scholar
• Goova MT, Li J, Kislinger T et al. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am. J. Pathol.159(2), 513–525 (2001).
   PubMed Web of Science ®Google Scholar
• Pachydaki SI, Tari SR, Lee SE et al. Upregulation of RAGE and its ligands in proliferative retinal disease. Exp. Eye Res.82(5), 807–815 (2006).
   PubMed Web of Science ®Google Scholar
• Hori O, Brett J, Slattery T et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J. Biol. Chem.270(43), 25752–25761 (1995).
   PubMed Web of Science ®Google Scholar
• Hofmann MA, Drury S, Fu C et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell97(7), 889–901 (1999).
   PubMed Web of Science ®Google Scholar
• Kosaki A, Hasegawa T, Kimura T et al. Increased plasma S100A12 (EN-RAGE) levels in patients with Type 2 diabetes. J. Clin. Endocrinol. Metab.89(11), 5423–5428 (2004).
   PubMed Web of Science ®Google Scholar
• Hasegawa T, Kosaki A, Kimura T et al. The regulation of EN-RAGE (S100A12) gene expression in human THP-1 macrophages. Atherosclerosis171(2), 211–218 (2003).
   PubMed Web of Science ®Google Scholar
• Kim MH, Choi YW, Choi HY, Myung KB, Cho SN. The expression of RAGE and EN-RAGE in leprosy. Br. J. Dermatol.154(4), 594–601 (2006).
   PubMedGoogle Scholar
• Ehlermann P, Eggers K, Bierhaus A et al. Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products. Cardiovasc. Diabetol.5, 6 (2006).
   PubMed Web of Science ®Google Scholar
• Zhou Z, Wang K, Penn MS et al. Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation107(17), 2238–2243 (2003).
   PubMed Web of Science ®Google Scholar
• Taguchi A, Blood DC, del Toro G et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature405(6784), 354–360 (2000).
   PubMed Web of Science ®Google Scholar
• Fiuza C, Bustin M, Talwar S et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood101(7), 2652–2660 (2003).
   PubMed Web of Science ®Google Scholar
• Rouhiainen A, Kuja-Panula J, Wilkman E et al. Regulation of monocyte migration by amphoterin (HMGB1). Blood104(4), 1174–1182 (2004).
   PubMed Web of Science ®Google Scholar
• Donahue JE, Flaherty SL, Johanson CE et al. RAGE, LRP-1, and amyloid-β protein in Alzheimer’s disease. Acta Neuropathol. (Berl.)112(4), 405–415 (2006).
   PubMed Web of Science ®Google Scholar
• Mruthinti S, Buccafusco JJ, Hill WD et al. Autoimmunity in Alzheimer's disease: increased levels of circulating IgGs binding Aβ and RAGE peptides. Neurobiol. Ageing25(8), 1023–1032 (2004).
   PubMed Web of Science ®Google Scholar
• Chaney MO, Stine WB, Kokjohn TA et al. RAGE and amyloid β interactions: atomic force microscopy and molecular modeling. Biochim. Biophys. Acta1741(1–2), 199–205 (2005).
   PubMed Web of Science ®Google Scholar
• Yan SD, Stern D, Kane MD et al. RAGE-Aβ interactions in the pathophysiology of Alzheimer’s disease. Restor. Neurol. Neurosci.12(2–3), 167–173 (1998).
   PubMedGoogle Scholar
• Chavakis T, Bierhaus A, Al-Fakhri N et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J. Exp. Med.198(10), 1507–1515 (2003).
   PubMed Web of Science ®Google Scholar
• Yokoi M, Yamagishi SI, Takeuchi M et al. Elevations of AGE and vascular endothelial growth factor with decreased total antioxidant status in the vitreous fluid of diabetic patients with retinopathy. Br. J. Ophthalmol.89(6), 673–675 (2005).
   PubMed Web of Science ®Google Scholar
• Renard C, Chappey O, Wautier MP et al. Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. Mol. Pharmacol.52(1), 54–62 (1997).
   PubMed Web of Science ®Google Scholar
• Sakurai S, Yamamoto Y, Tamei H et al. Development of an ELISA for sRAGE and its application to Type 1 diabetic patients. Diabetes Res. Clin. Pract.73(2), 158–165 (2006).
   PubMed Web of Science ®Google Scholar
• Yamagishi S, Adachi H, Nakamura K et al. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism55(9), 1227–1231 (2006).
   PubMed Web of Science ®Google Scholar
• Tan KC, Shiu SW, Chow WS et al. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in Type 2 diabetes. Diabetologia49(11), 2756–2762 (2006).
   PubMed Web of Science ®Google Scholar
• Miura J, Uchigata Y, Yamamoto Y et al. AGE down-regulation of monocyte RAGE expression and its association with diabetic complications in Type 1 diabetes. J. Diabetes Complications18(1), 53–59 (2004).
   PubMedGoogle Scholar
• Hou FF, Ren H, Owen WF Jr et al. Enhanced expression of receptor for advanced glycation end products in chronic kidney disease. J. Am. Soc. Nephrol.15(7), 1889–1896 (2004).
   PubMed Web of Science ®Google Scholar
• Marx N, Walcher D, Ivanova N et al. Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products. Diabetes53(10), 2662–2668 (2004).
   PubMed Web of Science ®Google Scholar
• Yamagishi S, Takeuchi M. Nifedipine inhibits gene expression of receptor for advanced glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation. Drugs Exp. Clin. Res.30(4), 169–175 (2004).
   PubMedGoogle Scholar
• Wang K, Zhou Z, Zhang M et al. Peroxisome proliferator-activated receptor γ down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model. J. Pharmacol. Exp. Ther.317(1), 37–43 (2006).
   PubMed Web of Science ®Google Scholar
• Yamagishi S, Nakamura K, Matsui T, Sato T, Takeuchi M. Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy. Med. Hypotheses66(5), 1019–1021 (2006).
   PubMedGoogle Scholar
• Yamagishi S, Takeuchi M, Matsui T et al. Angiotensin II augments advanced glycation end product-induced pericyte apoptosis through RAGE overexpression. FEBS Lett.579(20), 4265–4270 (2005).
   PubMed Web of Science ®Google Scholar
• Koka V, Wang W, Huang XR et al. Advanced glycation end products activate a chymase-dependent angiotensin II-generating pathway in diabetic complications. Circulation113(10), 1353–1360 (2006).
   PubMed Web of Science ®Google Scholar
• Nakamura K, Yamagishi S, Nakamura Y et al. Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvasc. Res.70(3), 137–141 (2005).
   PubMed Web of Science ®Google Scholar
• Stitt AW. The role of advanced glycation in the pathogenesis of diabetic retinopathy. Exp. Mol. Pathol.75, 95–108 (2003).
   PubMed Web of Science ®Google Scholar